Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo Pursues Optimal Promotion Mixes
March 9, 2009
- Astellas to Diversify Development Programs
March 9, 2009
- Teva-Kowa Aims at Becoming a Leading GE Maker in Japan in 2015
March 9, 2009
- R&D NEWS IN BRIEF
March 9, 2009
- Shire Enters Japanese Market by Opening Office in Tokyo
March 9, 2009
- RDKK Maintains Higher-Than-Industry-Average Growth Rate
March 9, 2009
- Abbott Japan Acquires Rights to Market Amitiza in Japan
March 9, 2009
- Review Period Reduced, but Submittal Lag Still Long: ACCJ Report
March 9, 2009
- BUSINESS NEWS IN BRIEF
March 9, 2009
- Council Starts Deliberating Online Sale of OTC Drugs
March 9, 2009
- Drugs Detected in Water from Tap Water Sources
March 9, 2009
- Fewer OTC Drug Wholesalers Report Profits despite Increases in Sales: FJPWA Survey
March 9, 2009
- 11 APIs Recommended for Approval
March 9, 2009
- MEDICAL DEVICE NEWS IN BRIEF
March 2, 2009
- Bayer Yakuhin: Wellnara for Postmenopausal Osteoporosis
March 2, 2009
- Skirmishes Heat Up between Pro- and Anti-Online Drug Sale Camps
March 2, 2009
- Project Begun in Order to Verify Usefulness of MD Studies
March 2, 2009
- Group of LDP Lawmakers to Draft Bill to Restrict Online Sale of OTC Drugs
March 2, 2009
- Shionogi's Velneperit Meets Primary Endpoint in 2 PIIb Trials
March 2, 2009
- Gov't to Issue Action Program and GL for New-Type Influenza
March 2, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…